Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT
Authors
Ortí, G.Gras, L.
Zinger, N.
Finazzi, M. C.
Sockel, K.
Robin, M.
Forcade, E.
Avenoso, D.
Kröger, N.
Finke, J.
Radujkovic, A.
Hunault-Berger, M.
Schroyens, W.
Zuckerman, T.
Bourhis, J. H.
Chalandon, Y.
Bloor, Adrian
Schots, R.
de Wreede, L. C.
Drozd-Sokolowska, J.
Raj, K.
Polverelli, N.
Czerw, T.
Hernández-Boluda, J. C.
McLornan, D.
Yakoub-Agha, I.
Affiliation
Department of Hematology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainIssue Date
2023
Metadata
Show full item recordAbstract
Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.Citation
Ortí G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, et al. Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT. American journal of hematology. 2023 Jan 6. PubMed PMID: 36606718. Epub 2023/01/07. eng.Journal
American Journal of HematologyDOI
10.1002/ajh.26833PubMed ID
36606718Additional Links
https://dx.doi.org/10.1002/ajh.26833Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/ajh.26833